Abstract
Originally identified as a gene specifically induced by IL-9 in a mouse T cell lymphoma, IL-22 is mainly produced by TH1 cells or by activated T cells. Human IL-22, which shares 79% amino acid identity with its mouse orthologue and 25% with IL-10 is encoded by a single copy gene and located on chromosome 12, close to the IFNγ gene, whereas the murine IL-22 gene is located on chromosome 10 and is duplicated in some mouse strains. Structurally, IL-22 appears to be a monomer composed of six alpha helices, whose organization is reminiscent of the helices of the IL-10 dimer. Despite its structural relationship with IL-10, IL-22 exerts completely different activities, acting mainly on non hematopoietic cells, such as epithelial cells from lung and colon, hepatocytes and keratinocytes. IL-22 might therefore be involved in inflammatory processes, at least in liver and skin. IL-22 exerts its activity via a complex formed by IL-10Rβ and IL-22R, associated with Tyk2 and Jak1, respectively. The main signaling pathways triggered by IL-22 involve STAT-1, - 3, -5 and the ERK, JNK and p38 MAPKinases. Beside its transmembrane receptor, IL-22 also binds to a soluble receptor, called IL-22BP. This soluble receptor turns out to be a natural antagonist of IL-22 biological activities at least in vitro.
Keywords: IL-22, inflammation, receptors
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: IL-22 and Its Receptors, New Players in the Inflammatory Network
Volume: 5 Issue: 3
Author(s): Laure Dumoutier and Jean-Christophe Renauld
Affiliation:
Keywords: IL-22, inflammation, receptors
Abstract: Originally identified as a gene specifically induced by IL-9 in a mouse T cell lymphoma, IL-22 is mainly produced by TH1 cells or by activated T cells. Human IL-22, which shares 79% amino acid identity with its mouse orthologue and 25% with IL-10 is encoded by a single copy gene and located on chromosome 12, close to the IFNγ gene, whereas the murine IL-22 gene is located on chromosome 10 and is duplicated in some mouse strains. Structurally, IL-22 appears to be a monomer composed of six alpha helices, whose organization is reminiscent of the helices of the IL-10 dimer. Despite its structural relationship with IL-10, IL-22 exerts completely different activities, acting mainly on non hematopoietic cells, such as epithelial cells from lung and colon, hepatocytes and keratinocytes. IL-22 might therefore be involved in inflammatory processes, at least in liver and skin. IL-22 exerts its activity via a complex formed by IL-10Rβ and IL-22R, associated with Tyk2 and Jak1, respectively. The main signaling pathways triggered by IL-22 involve STAT-1, - 3, -5 and the ERK, JNK and p38 MAPKinases. Beside its transmembrane receptor, IL-22 also binds to a soluble receptor, called IL-22BP. This soluble receptor turns out to be a natural antagonist of IL-22 biological activities at least in vitro.
Export Options
About this article
Cite this article as:
Dumoutier Laure and Renauld Jean-Christophe, IL-22 and Its Receptors, New Players in the Inflammatory Network, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2006; 5 (3) . https://dx.doi.org/10.2174/187152306778017665
DOI https://dx.doi.org/10.2174/187152306778017665 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Targeted Approaches to Cancer Therapy and Prevention Using Chalcones
Current Cancer Drug Targets Summary of Information on the Effects of Ionizing and Non-ionizing Radiation on Cytochrome P450 and Other Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy
Current Pharmaceutical Biotechnology Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Biodistribution and Dosimetry of 177Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
Current Radiopharmaceuticals Chemokines as Pharmacological Targets
Mini-Reviews in Medicinal Chemistry Expression and Characterization of a Variant of TACI (CRD2-shortTACIFc) in Pichia pastoris
Protein & Peptide Letters Insight to Physiology and Pathology of Zinc(II) Ions and Their Actions in Breast and Prostate Carcinoma
Current Medicinal Chemistry Susceptibility of Periodontopathogenic and Cariogenic Bacteria to Defensins and Potential Therapeutic Use of Defensins in Oral Diseases
Current Pharmaceutical Design Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety Cytokine Gene Polymorphism in Heart Transplantation: A Review
Current Genomics Alkylboronate Synthesis Based on Transition Metal-Catalyzed Hydroboration.
Current Organic Synthesis BAFFling Autoimmune Disorders and Helicobacter pylori Disease: The Interplay between BAFF and the Th17 Response
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Natural Medicine:The Genus Angelica
Current Medicinal Chemistry Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
Current Molecular Medicine DNA Vaccination in Oncology: Current Status, Opportunities and Perspectives
Current Clinical Pharmacology The Inhibitor of Growth (ING) Gene Family: Potential Role in Cancer Therapy
Current Cancer Drug Targets Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors
Current Medicinal Chemistry Context-dependent Action of Transforming Growth Factor β Family Members on Normal and Cancer Stem Cells
Current Pharmaceutical Design Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery